While previous studies have shown both CD4+ and CD8+ T cells are important for the adaptive anti-tumor response following CpG+OX40 (11), ongoing research aims to understand the relative importance of these populations in the RT+CpG+OX40 regimen. The gene discussed is CD4; the disease is neoplasm.